• 简

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    CRISPR Therapeutics (CRSP) Names A New CFO, Is The 44% Undervaluation Real?

    Simply Wall St·10/25/2026 18:25:41
    语音播报

    CRISPR Therapeutics (CRSP) just reshuffled its top finance role, with long-time insider Andrew J. Silver promoted to Chief Financial Officer as Raju Prasad steps down to pursue external opportunities.

    CRISPR Therapeutics has been under pressure, with the share price down 8.9% over the past month and the 1 year total shareholder return declining 27%. However, the 3 year total shareholder return is up 27%, which suggests longer term holders have seen mixed momentum that contrasts with the recent CFO reshuffle and other headlines.

    Spot 21 high quality undiscovered gems that, like CRISPR Therapeutics after its CFO shake-up, combine complex stories with strong fundamentals that markets may not be fully pricing in yet.

    CRISPR Therapeutics now trades well below both analyst targets and one intrinsic value estimate, following a sharp pullback and the appointment of a new CFO. The key question is whether that gap reflects risk or potential mispricing that further valuation analysis can help clarify.

    Most Popular Narrative: 44% Undervalued

    CRISPR Therapeutics last closed at $49.39, while the most followed narrative anchors fair value near $87.56. This frames the recent CFO change against a valuation gap that many investors are trying to explain.

    Analysts expect earnings to reach $128.2 million (and earnings per share of $1.2) by about September 2029, up from -$451.1 million today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting $1.0 billion in earnings, and the most bearish expecting $-689.7 million.

    See why 13 investors see CRISPR Therapeutics as 44% undervalued.

    Result: Fair Value of $87.56 (UNDERVALUED)

    Still, CRISPR Therapeutics faces clear pressure points, including ongoing net losses relative to modest revenue and the possibility of future dilution from its convertible notes and shelf registration.

    Find out about the key risks to this CRISPR Therapeutics narrative.

    Next Steps

    Sentiment around CRISPR Therapeutics is clearly split. This is exactly when independent work matters most, so act while the narrative is still forming and pressure test the upside case through the 2 key rewards

    Looking for more investment ideas beyond CRISPR Therapeutics?

    If CRISPR Therapeutics has your attention, do not stop here. Fresh ideas often emerge where fewer investors are looking and where fundamentals still do the talking.